Navigation Links
Solos Endoscopy, Inc. Set To Develop European Union Conforming CE Mark Technical File

BOSTON, March 2 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce the Company has signed an agreement with Expert Resource (ER) to provide consulting services in support of the Company's CE Mark Technical File development. Before Solos can place the CE Marking on their medical devices and legally sell within the European Union (EU) and Canada, the Company must prepare a Technical File with evidence of compliance to the EU Medical Device Directive. ER's services, in cooperation with Solos, include the verification of the essential requirements and a risk assessment according to ISO 14971 (Risk Management). According to a 2009 report published by Frost & Sullivan, the EU represents $94 Billion, or 30%, of the worldwide demand for medical instruments.

Expert Resource is an international consulting and training firm specializing in business improvement initiatives. ER helps medical device and medical laboratory companies implement ISO 13485, ISO 15189, ISO 14971, or GMP quality systems, obtain the CE Mark, submit FDA 510(k) applications, assist with clinical trials, and more. For more information on Expert Resource, visit

"Expanding into the EU and Canada presents enormous sales opportunities for Solos Endoscopy. We are pleased to be working with Expert Resource to provide the specialized assistance we need in obtaining the CE Mark for our medical devices," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.

Back to top



SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
2. Solos Endoscopy, Inc.s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress
3. Solos Endoscopy, Inc.s FDA Approved MammoView(TM) Product Line to Obtain CE Mark
4. Solos Endoscopy, Inc. Receives Multiple Purchase Orders for its MammoView(TM) Product Line
5. Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line
6. Solos Endoscopy, Inc. Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Product Line
7. Solos Endoscopy, Inc. Receives Purchase Orders from Catholic Health Initiatives for its MammoView(TM) Product Line
8. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine
9. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in February Issue of General Surgery News
10. Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010
11. Solos Endoscopy, Inc. Outlines Marketing Strategy for 2010 Campaign
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
Breaking Medicine News(10 mins):